USD 0.0
(0.0%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2021 | 11.23 Million USD | 584.77% |
2020 | -2.31 Million USD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2022 Q2 | 2.89 Million USD | -13.65% |
2022 Q1 | 3.34 Million USD | 0.0% |
2021 FY | 11.23 Million USD | 584.77% |
2021 Q2 | 2.22 Million USD | 0.0% |
2020 FY | -2.31 Million USD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
AstraZeneca PLC | 34.69 Billion USD | 99.968% |
Bristol-Myers Squibb Company PFD CONV 2 | 34.31 Billion USD | 99.967% |
CSPC Pharmaceutical Group Limited | 30.13 Billion USD | 99.963% |
Novartis AG | 34.18 Billion USD | 99.967% |
PT Kalbe Farma Tbk. | 743.47 Million USD | 98.489% |